• 1
    Carlsson A, Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol (Copenh) 1963;20:140144.
  • 2
    van Rossum JM. The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs. Arch Int Pharmacodyn Ther 1966;160:492494.
  • 3
    Snyder SH. Overview of neurotransmitter receptor binding. In: YamamuraHI, editor Neurotransmitter receptor binding New York : Raven Press, 1978;111.
  • 4
    Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976;192:481483.
  • 5
    Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976;261:717719.
  • 6
    Kebabian JW, Calne DB. Multiple receptors for dopamine. Nature 1979;277:9396.
  • 7
    Peroutka SJ, Snyder SH. Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic, and histamine receptors to clinical potency. Am J Psychiatry 1980;137:15181522.
  • 8
    Wagner HN, Jr., Burns HD, Dannals RF, et al. Imaging dopamine receptors in the human brain by positron tomography. Science 1983;221:12641266.
  • 9
    Elsinga PH, Hatano K, Ishiwata K. PET tracers for imaging of the dopaminergic system. Curr Med Chem 2006;13:21392153.
  • 10
    Farde L, Ehrin E, Eriksson L, et al. Substituted benzamides as ligands for visualization of dopamine receptor binding in the human brain by positron emission tomography. Proc Natl Acad Sci U S A 1985;82:38633867.
  • 11
    Litton J, Bergstrom M, Eriksson L, Bohm C, Blomqvist G, Kesselberg M. Performance study of the PC-384 positron camera system for emission tomography of the brain. J Comput Assist Tomogr 1984;8:7487.
  • 12
    Varrone A, Sjoholm N, Eriksson L, Gulyas B, Halldin C, Farde L. Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT. Eur J Nucl Med Mol Imaging 2009;36:16391650.
  • 13
    Cambon H, Baron JC, Boulenger JP, Loc’h C, Zarifian E, Maziere B. In vivo assay for neuroleptic receptor binding in the striatum. Positron tomography in humans. Br J Psychiatry 1987;151:824830.
  • 14
    Farde L, Hall H, Ehrin E, Sedvall G. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science 1986;231:258261.
  • 15
    Smith M, Wolf AP, Brodie JD, et al. Serial [18F]N-methylspiroperidol PET studies to measure changes in antipsychotic drug D-2 receptor occupancy in schizophrenic patients. Biol Psychiatry 1988;23:653663.
  • 16
    Maziere B, Loc’h C, Baron JC, Sgouropoulos P, Duquesnoy N, D’Antona R, Cambon H. In vivo quantitative imaging of dopamine receptors in human brain using positron emission tomography and [76Br]bromospiperone. Eur J Pharmacol 1985;114:267272.
  • 17
    Farde L, Wiesel FA, Halldin C, Sedvall G. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 1988;45:7176.
  • 18
    Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 1992;49:538544.
  • 19
    Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000;157:514520.
  • 20
    Nordstrom AL, Farde L, Wiesel FA, Forslund K, Pauli S, Halldin C, Uppfeldt G. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: A double-blind PET study of schizophrenic patients. Biol Psychiatry 1993;33:227235.
  • 21
    Klemm E, Grunwald F, Kasper S, et al. [123I]IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics. Am J Psychiatry 1996;153:183190.
  • 22
    Nyberg S, Farde L. Non-equipotent doses partly explain differences among antipsychotics: Implications of PET studies. Psychopharmacology (Berl) 2000;148:2223.
  • 23
    Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789796.
  • 24
    Remington G, Kapur S. Atypical antipsychotics: Are some more atypical than others? Psychopharmacology (Berl) 2000;148:315.
  • 25
    Nordstrom AL, Farde L, Nyberg S, Karlsson P, Halldin C, Sedvall G. D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: A PET study of schizophrenic patients. Am J Psychiatry 1995;152:14441449.
  • 26
    Pilowsky LS, Costa DC, Ell PJ, Murray RM, Verhoeff NP, Kerwin RW. Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia. Lancet 1992;340:199202.
  • 27
    Farde L, Wiesel FA, Nordstrom AL, Sedvall G. D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology (Berl) 1989;99(Suppl):S2831.
  • 28
    Lee CM, Farde L. Using positron emission tomography to facilitate CNS drug development. Trends Pharmacol Sci 2006;27:310316.
  • 29
    Farde L. The advantage of using positron emission tomography in drug research. Trends Neurosci 1996;19:211214.
  • 30
    Lieberman JA, Golden R, Stroup S, McEvoy J. Drugs of the psychopharmacological revolution in clinical psychiatry. Psychiatr Serv 2000;51:12541258.
  • 31
    Nyberg S, Eriksson B, Oxenstierna G, Halldin C, Farde L. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. Am J Psychiatry 1999;156:869875.
  • 32
    Nordstrom AL, Nyberg S, Olsson H, Farde L. Positron emission tomography finding of a high striatal D2 receptor occupancy in olanzapine-treated patients. Arch Gen Psychiatry 1998;55:283284.
  • 33
    Kapur S, Zipursky RB, Remington G, Jones C, DaSilva J, Wilson AA, Houle S. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: A PET investigation. Am J Psychiatry 1998;155:921928.
  • 34
    Silva RR. Psychopharmacology news. J Child Adolesc Psychopharmacol 2001;11:111112.
  • 35
    Citrome L. Using oral ziprasidone effectively: The food effect and dose-response. Adv Ther 2009;26:739748.
  • 36
    Mamo D, Kapur S, Shammi CM, Papatheodorou G, Mann S, Therrien F, Remington G. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry 2004;161:818825.
  • 37
    Corripio I, Catafau AM, Perez V, et al. Striatal dopaminergic D2 receptor occupancy and clinical efficacy in psychosis exacerbation: A 123I-IBZM study with ziprasidone and haloperidol. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:9196.
  • 38
    Gefvert O, Bergstrom M, Langstrom B, Lundberg T, Lindstrom L, Yates R. Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. Psychopharmacology (Berl) 1998;135:119126.
  • 39
    Gefvert O, Lundberg T, Wieselgren IM, Bergstrom M, Langstrom B, Wiesel F, Lindstrom L. D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: A PET study. Eur Neuropsychopharmacol 2001;11:105110.
  • 40
    Mamo DC, Uchida H, Vitcu I, Barsoum P, Gendron A, Goldstein J, Kapur S. Quetiapine extended-release versus immediate-release formulation: A positron emission tomography study. J Clin Psychiatry 2008;69:8186.
  • 41
    Baldwin CM, Scott LJ. Quetiapine extended release: In schizophrenia. CNS Drugs 2009;23:261269.
  • 42
    DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: An atypical antipsychotic. Clin Pharmacokinet 2001;40:509522.
  • 43
    Tauscher-Wisniewski S, Kapur S, Tauscher J, et al. Quetiapine: An effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade. J Clin Psychiatry 2002;63:992997.
  • 44
    Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P. A positron emission tomography study of quetiapine in schizophrenia: A preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 2000;57:553559.
  • 45
    Kegeles LS, Slifstein M, Frankle WG, et al. Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride. Neuropsychopharmacology 2008;33:31113125.
  • 46
    Mamo D, Graff A, Mizrahi R, Shammi CM, Romeyer F, Kapur S. Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: A triple tracer PET study. Am J Psychiatry 2007;164:14111417.
  • 47
    Grunder G, Fellows C, Janouschek H, et al. Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: An [18F]fallypride PET study. Am J Psychiatry 2008;165:988995.
  • 48
    Yokoi F, Grunder G, Biziere K, et al. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): A study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology 2002;27:248259.
  • 49
    Swainston Harrison T, Perry CM. Aripiprazole: A review of its use in schizophrenia and schizoaffective disorder. Drugs 2004;64:17151736.
  • 50
    Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: A critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 2005;10:79104.
  • 51
    Seeman P, Guan HC, Van Tol HH. Dopamine D4 receptors elevated in schizophrenia. Nature 1993;365:441445.
  • 52
    Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990;347:14651.
  • 53
    Schwartz JC, Levesque D, Martres MP, Sokoloff P. Dopamine D3 receptor: Basic and clinical aspects. Clin Neuropharmacol 1993;16:295314.
  • 54
    Graff-Guerrero A, Willeit M, Ginovart N, et al. Brain region binding of the D2/3 agonist [11C]-(+)-PHNO and the D2/3 antagonist [11C]raclopride in healthy humans. Hum Brain Mapp 2008;29:400410.
  • 55
    Narendran R, Slifstein M, Guillin O, et al. Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [11C]-(+)-PHNO is a D3 receptor preferring agonist in vivo. Synapse 2006;60:485495.
  • 56
    Graff-Guerrero A, Mamo D, Shammi CM, et al. The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: A positron emission tomography study With [11C]-(+)-PHNO. Arch Gen Psychiatry 2009;66:606615.
  • 57
    Searle G, Beaver JD, Comley RA, et al. Imaging dopamine D3 receptors in the human brain with positron emission tomography, [11C]PHNO, and a selective D3 receptor antagonist. Biol Psychiatry 2010;68:392399.
  • 58
    Van Tol HH, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB, Civelli O. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 1991;350:610614.
  • 59
    Tauscher J, Hussain T, Agid O, et al. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: Differentiation from other atypical antipsychotics. Am J Psychiatry 2004;161:16201625.
  • 60
    Richelson E. Receptor pharmacology of neuroleptics: Relation to clinical effects. J Clin Psychiatry 1999;60(Suppl 10):514.
  • 61
    Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007;27:15331539.
  • 62
    Nyberg S, Nordstrom AL, Halldin C, Farde L. Positron emission tomography studies on D2 dopamine receptor occupancy and plasma antipsychotic drug levels in man. Int Clin Psychopharmacol 1995;10(Suppl 3):8185.
  • 63
    Baron JC, Martinot JL, Cambon H, et al. Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: Correlative evaluation by positron emission tomography and plasma prolactin levels. Psychopharmacology (Berl) 1989;99:463472.
  • 64
    Catafau AM, Penengo MM, Nucci G, et al. Pharmacokinetics and time-course of D(2) receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients. J Psychopharmacol 2008;22:882894.
  • 65
    Nyberg S, Farde L, Halldin C, Dahl ML, Bertilsson L. D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am J Psychiatry 1995;152:173178.
  • 66
    Uchida H, Mamo DC, Kapur S, et al. Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia. J Clin Psychiatry 2008;69:12811286.
  • 67
    Ogren SO, Hall H, Kohler C, Magnusson O, Lindbom LO, Angeby K, Florvall L. Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain. Eur J Pharmacol 1984;102:459474.
  • 68
    Arnt J, Skarsfeldt T, Hyttel J. Differentiation of classical and novel antipsychotics using animal models. Int Clin Psychopharmacol 1997;12(Suppl 1):S917.
  • 69
    Deutch AY. Identification of the neural systems subserving the actions of clozapine: Clues from immediate-early gene expression. J Clin Psychiatry 1994;55(Suppl B):3742.
  • 70
    Hall H, Kohler C, Gawell L, Farde L, Sedvall G. Raclopride, a new selective ligand for the dopamine-D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 1988;12:559568.
  • 71
    Olsson H, Halldin C, Swahn CG, Farde L. Quantification of [11C]FLB 457 binding to extrastriatal dopamine receptors in the human brain. J Cereb Blood Flow Metab 1999;19:11641173.
  • 72
    Mukherjee J, Christian BT, Dunigan KA, Shi B, Narayanan TK, Satter M, Mantil J. Brain imaging of 18F-fallypride in normal volunteers: Blood analysis, distribution, test-retest studies, and preliminary assessment of sensitivity to aging effects on dopamine D-2/D-3 receptors. Synapse 2002;46:170188.
  • 73
    Kornhuber J, Brucke T, Angelberger P, Asenbaum S, Podreka I. SPECT imaging of dopamine receptors with [123I]epidepride: Characterization of uptake in the human brain. J Neural Transm Gen Sect 1995;101:95103.
  • 74
    Kuikka JT, Akerman KK, Hiltunen J, et al. Striatal and extrastriatal imaging of dopamine D2 receptors in the living human brain with [123I]epidepride single-photon emission tomography. Eur J Nucl Med. 1997;24:483487.
  • 75
    Kessler RM, Ansari MS, Riccardi P, Li R, Jayathilake K, Dawant B, Meltzer HY. Occupancy of striatal and extrastriatal dopamine D2/D3 receptors by olanzapine and haloperidol. Neuropsychopharmacology 2005;30:22832289.
  • 76
    Farde L, Suhara T, Nyberg S, Karlsson P, Nakashima Y, Hietala J, Halldin C. A PET-study of [11C]FLB 457 binding to extrastriatal D2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients. Psychopharmacology (Berl) 1997;133:396404.
  • 77
    Xiberas X, Martinot JL, Mallet L, Artiges E, Loc HC, Maziere B, Paillere-Martinot ML. Extrastriatal and striatal D(2) dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. Br J Psychiatry 2001;179:503508.
  • 78
    Bigliani V, Mulligan RS, Acton PD, et al. In vivo occupancy of striatal and temporal cortical D2/D3 dopamine receptors by typical antipsychotic drugs. [123I]epidepride single photon emission tomography (SPET) study. Br J Psychiatry 1999;175:231238.
  • 79
    Talvik M, Nordstrom AL, Nyberg S, Olsson H, Halldin C, Farde L. No support for regional selectivity in clozapine-treated patients: A PET study with [(11)C]raclopride and [(11)C]FLB 457. Am J Psychiatry 2001;158:926930.
  • 80
    Grunder G, Landvogt C, Vernaleken I, et al. The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia. Neuropsychopharmacology 2006;31:10271035.
  • 81
    Kessler RM, Ansari MS, Riccardi P, Li R, Jayathilake K, Dawant B, Meltzer HY. Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine. Neuropsychopharmacology 2006;31:19912001.
  • 82
    Pilowsky LS, Mulligan RS, Acton PD, Ell PJ, Costa DC, Kerwin RW. Limbic selectivity of clozapine. Lancet 1997;350:490491.
  • 83
    Erlandsson K, Bressan RA, Mulligan RS, Ell PJ, Cunningham VJ, Pilowsky LS. Analysis of D2 dopamine receptor occupancy with quantitative SPET using the high-affinity ligand [123I]epidepride: Resolving conflicting findings. Neuroimage 2003;19:12051214.
  • 84
    Olsson H, Farde L. Potentials and pitfalls using high affinity radioligands in PET and SPET determinations on regional drug induced D2 receptor occupancy–a simulation study based on experimental data. Neuroimage 2001;14:936945.
  • 85
    Ito H, Arakawa R, Takahashi H, et al. No regional difference in dopamine D2 receptor occupancy by the second-generation antipsychotic drug risperidone in humans: A positron emission tomography study. Int J Neuropsychopharmacol 2009;12:667675.
  • 86
    Tauscher J, Jones C, Remington G, Zipursky RB, Kapur S. Significant dissociation of brain and plasma kinetics with antipsychotics. Mol Psychiatry 2002;7:317321.
  • 87
    Yasuno F, Suhara T, Okubo Y, Sudo Y, Inoue M, Ichimiya T, Tanada S. Dose relationship of limbic-cortical D2-dopamine receptor occupancy with risperidone. Psychopharmacology (Berl) 2001;154:112114.
  • 88
    Bunzow JR, Van Tol HH, Grandy DK, et al. Cloning and expression of a rat D2 dopamine receptor cDNA. Nature 1988;336:783787.
  • 89
    Grandy DK, Marchionni MA, Makam H, et al. Cloning of the cDNA and gene for a human D2 dopamine receptor. Proc Natl Acad Sci U S A 1989;86:97629766.
  • 90
    Dal Toso R, Sommer B, Ewert M, et al. The dopamine D2 receptor: Two molecular forms generated by alternative splicing. EMBO J. 1989;8:40254034.
  • 91
    Selbie LA, Hayes G, Shine J. The major dopamine D2 receptor: Molecular analysis of the human D2A subtype. DNA 1989;8:683689.
  • 92
    Picetti R, Saiardi A, Abdel Samad T, Bozzi Y, Baik JH, Borrelli E. Dopamine D2 receptors in signal transduction and behavior. Crit Rev Neurobiol 1997;11:121142.
  • 93
    Usiello A, Baik JH, Rouge-Pont F, et al. Distinct functions of the two isoforms of dopamine D2 receptors. Nature 2000;408:199203.
  • 94
    Malmberg A, Jackson DM, Eriksson A, Mohell N. Unique binding characteristics of antipsychotic agents interacting with human dopamine D2A, D2B, and D3 receptors. Mol Pharmacol 1993;43:749754.
  • 95
    Farde L, Hall H, Pauli S, Halldin C. Variability in D2-dopamine receptor density and affinity: A PET study with [11C]raclopride in man. Synapse 1995;20:200208.